Literature DB >> 7004532

Prevention of graft rejection following bone marrow transplantation.

R P Gale, W Ho, S Feig, R Champlin, A Tesler, E Arenson, S Ladish, L Young, D Winston, R Sparkes, J Fitchen, M Territo, G Sarna, L Wong, Y Paik, Y Bryson, D Golde, J Fahey, M Cline.   

Abstract

Bone marrow transplantation from an HLA-identical sibling is increasingly used in the treatment of severe aplastic anemia. One major problem with this approach is graft rejection that occurs in 25%-60% of patients conditioned for transplantation with cyclophosphamide. At most transplant centers it has been difficult to accurately identify patients at high risk for graft rejection. We studied a conditioning regimen of cyclophosphamide (200 mg per kg) and low-dose total body irradiation (3 Gy; equivalent to 300 rad) in 23 consecutive unselected patients with aplastic anemia followed for a minimum of 6 mo. There was only one episode of graft rejection. Graft-versus-host disease and interstitial pneumonitis were not increased by the more intensive conditioning regimen. Actuarial survival was 61% at 1 yr and 49% at 2.5 yr. Cyclophosphamide and low-dose total body irradiation is an effective conditioning regimen in patients with aplastic anemia. It may be particularly useful when accurate predictive tests of graft rejection are not available as is the case in most transplant centers.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7004532

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  12 in total

1.  Survival and quality of life in 23 patients with severe aplastic anemia treated with bone marrow transplantation (BMT).

Authors:  W Hinterberger; H Gadner; P Höcker; A Hajek-Rosenmayr; W Graninger; G Grabner; B Volc-Platzer; R Hawliczek; K H Kärcher; W Kallinger
Journal:  Blut       Date:  1987-03

Review 2.  Progress in bone marrow transplantation in man.

Authors:  R P Gale
Journal:  Surv Immunol Res       Date:  1982

3.  Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN).

Authors:  Naynesh R Kamani; Mark C Walters; Shelly Carter; Victor Aquino; Joel A Brochstein; Sonali Chaudhury; Mary Eapen; Brian M Freed; Michael Grimley; John E Levine; Brent Logan; Theodore Moore; Julie Panepinto; Suhag Parikh; Michael A Pulsipher; Jane Sande; Kirk R Schultz; Stephen Spellman; Shalini Shenoy
Journal:  Biol Blood Marrow Transplant       Date:  2012-02-16       Impact factor: 5.742

Review 4.  Preparation for bone marrow transplantation.

Authors:  R Parkman
Journal:  Springer Semin Immunopathol       Date:  1984

5.  Bone marrow transplantation in children.

Authors:  S Storch; S A Feig; R P Gale
Journal:  Indian J Pediatr       Date:  1982 May-Jun       Impact factor: 1.967

6.  Recent developments in allogeneic marrow transplantation for the treatment of severe aplastic anemia.

Authors:  R Storb
Journal:  Blut       Date:  1981-12

7.  Prevention and treatment of cytomegalovirus infections with interferons and immune globulins.

Authors:  J D Meyers
Journal:  Infection       Date:  1985       Impact factor: 3.553

8.  Safety and tolerance of recombinant leukocyte A interferon in bone marrow transplant recipients.

Authors:  D J Winston; W G Ho; R W Schroff; R E Champlin; R P Gale
Journal:  Antimicrob Agents Chemother       Date:  1983-06       Impact factor: 5.191

9.  Abnormalities of myeloid progenitor cells after "successful" bone marrow transplantation.

Authors:  S Li; R Champlin; J H Fitchen; R P Gale
Journal:  J Clin Invest       Date:  1985-01       Impact factor: 14.808

10.  Prevention and treatment of cytomegalovirus infections with interferons and immune globulins.

Authors:  J D Meyers
Journal:  Infection       Date:  1984 Mar-Apr       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.